Castle Biosciences (NASDAQ:CSTL) Trading Up 9.3% – What’s Next?

Castle Biosciences, Inc. (NASDAQ:CSTL)’s share price was up 9.3% on Wednesday . The company traded as high as $21.81 and last traded at $21.5150. Approximately 174,559 shares traded hands during trading, a decline of 57% from the average daily volume of 403,417 shares. The stock had previously closed at $19.69.

Analyst Ratings Changes

A number of brokerages have recently commented on CSTL. KeyCorp reaffirmed an “overweight” rating and issued a $50.00 price objective on shares of Castle Biosciences in a research report on Thursday, January 29th. Weiss Ratings lowered Castle Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, May 7th. Wall Street Zen downgraded shares of Castle Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Morgan Stanley upgraded shares of Castle Biosciences to a “buy” rating in a report on Monday, March 2nd. Finally, Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Castle Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.33.

Castle Biosciences Stock Up 3.9%

The company has a current ratio of 6.75, a quick ratio of 6.53 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $670.11 million, a price-to-earnings ratio of -50.21 and a beta of 1.11. The firm has a 50 day moving average price of $23.06 and a two-hundred day moving average price of $31.43.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.49) EPS for the quarter, meeting the consensus estimate of ($0.49). Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. The firm had revenue of $84.23 million for the quarter, compared to analyst estimates of $79.23 million. On average, equities analysts expect that Castle Biosciences, Inc. will post -1.4 earnings per share for the current fiscal year.

Insider Activity

In other news, Director G Bradley Cole sold 7,403 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $28.47, for a total value of $210,763.41. Following the completion of the transaction, the director directly owned 19,309 shares in the company, valued at approximately $549,727.23. This represents a 27.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tobin W. Juvenal sold 20,863 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $25.24, for a total value of $526,582.12. Following the sale, the insider owned 86,825 shares of the company’s stock, valued at $2,191,463. This represents a 19.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 88,583 shares of company stock valued at $2,250,288. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Castle Biosciences

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Castle Biosciences by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock valued at $85,573,000 after acquiring an additional 27,511 shares in the last quarter. RTW Investments LP bought a new position in shares of Castle Biosciences during the fourth quarter worth about $82,283,000. Principal Financial Group Inc. grew its stake in Castle Biosciences by 0.7% in the fourth quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock worth $70,317,000 after purchasing an additional 13,289 shares in the last quarter. Portolan Capital Management LLC increased its holdings in Castle Biosciences by 1.7% in the third quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company’s stock valued at $34,499,000 after buying an additional 25,539 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Castle Biosciences by 7.0% in the third quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock valued at $33,564,000 after buying an additional 96,084 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.